$TEVA

Friday on the Tel Aviv Stock Exchange, major indices declined. Tel Aviv 35 fell 0.33% to 4,202.63 and Tel Aviv 125 fell 0.31% to 4,074.63. Defense and renewable energy sector indices dropped, while chemicals rubber and plastics rose. FX rates weakened versus the dollar and euro. Bank Hapoalim rose 0.31%, Tower Semiconductor fell 4.35%, Teva fell 2.28%.

Teva Pharmaceutical Industries (NYSE:TEVA) moved its anti-IL-15 antibody TEV-408 into a Phase 2b trial for nonsegmental vitiligo after Phase 1b data showed repigmentation and a favorable safety profile, according to the article. TEVA shares closed at $36.77, up 16.51% over 30 days, with 1-year total return of 105.88%. The piece cites fair value at $40.90 and revenue above $17.3b.

A public advisory says two lots of Teva pregabalin 150 mg capsules were recalled due to possible cross-contamination with sertraline. The notice advises patients to stop the product and seek emergency care for serious allergic reactions, and to consult a clinician before stopping otherwise. Customers should return the recalled items to the pharmacy for replacement or disposal.

Moody’s Ratings upgraded Teva Pharmaceutical Industries (NYSE:TEVA) to investment grade, raising its issuer rating to Baa3 from Ba1 and changing the outlook to stable from positive. Moody’s cited branded sales growth, pipeline expansion, and deleveraging. It expects gross debt/EBITDA to fall below 3.75x, and forecasts about $2.0B free cash flow over 12 months.

Teva Pharmaceutical Industries (NYSE: TEVA) said Moody’s upgraded its corporate credit rating to Baa3 from Ba1 with a stable outlook. Moody’s cited execution of Teva’s Pivot to Growth strategy, including growth products, pipeline expansion, and continued debt reduction supported by earnings growth, plus improving margins and free cash flow. Teva expects further debt reduction over 12 to 18 months.

Israeli drugmaker Teva Pharmaceuticals asked a U.S. judge to bar insurer Humana from telling jurors Teva is Israeli in a generic drug price-fixing trial. Teva said its corporate origin is irrelevant to alleged price inflation of drugs including baclofen and propranolol. The trial is set to start Sept. 15 in Philadelphia.

Teva Pharmaceutical Industries asked a U.S. judge to bar Humana’s lawsuit from telling jurors that Teva is Israeli-based, saying the references could be prejudicial and irrelevant. The case, Humana Inc. v. Actavis Elizabeth, LLC, et al., is set for trial Sept. 15 in Philadelphia federal court. Teva denies price-fixing allegations.

Teva (TEVA) reported Q2 2026 revenue of $4.1B, down 1% year over year due to lower U.S. generic sales. Innovative brands rose, including AUSTEDO $696M (+40%), AJOVY $244M (+56%), and UZEDY $77M (+43%). Non-GAAP EPS was $0.02 and free cash flow was $622M (+31%). 2026 revenue guidance was raised to $16.5B-$16.85B; net debt was $12.9B (2.8x).

In Humana Inc. v. Actavis Elizabeth LLC, et al. (EDPA July 27, 2026), a judge held that facts admitted in a DOJ Deferred Prosecution Agreement are binding in follow-on civil antitrust cases. The ruling relied on Teva’s Rule 36 admissions quoting its DPA Statement of Facts, granting partial summary judgment on a Section 1 per se price-fixing claim.

Teva Pharmaceuticals USA asked a U.S. federal judge to bar references to its Israeli identity in an upcoming antitrust trial. In a motion in Pennsylvania, Teva said its nationality and ties to Israel are irrelevant to allegations of generic drug price-fixing and market allocation. Teva cited Pew polling showing 60% unfavorable views of Israel in the U.S. and argued Israel-related references could bias jurors.